LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Central Nervous System Lymphoma: Novel Therapies.

    Fortin Ensign, Shannon P / Gathers, Diamone / Wiedmeier, Julia Erin / Mrugala, Maciej M

    Current treatment options in oncology

    2022  Volume 23, Issue 1, Page(s) 117–136

    Abstract: Opinion statement: Primary central nervous system lymphomas (PCNSLs) are very rare neoplasms and continue to be challenging to treat. While high-dose methotrexate (HD-MTX)-based regimens are the currently accepted standard first-line therapy for newly ... ...

    Abstract Opinion statement: Primary central nervous system lymphomas (PCNSLs) are very rare neoplasms and continue to be challenging to treat. While high-dose methotrexate (HD-MTX)-based regimens are the currently accepted standard first-line therapy for newly diagnosed patients, the optimal induction therapies are still unknown. The role of consolidation therapies continues to evolve with a variety of chemotherapy regimens, including high-dose chemotherapy with stem cell rescue and reduced or deferred whole brain radiotherapy being used. Importantly, several recent advances have been made in the treatment of PCNSL. The incorporation of targeted therapy and immune therapy remain promising strategies. Several agents, successfully used in treatment of systemic lymphomas, have shown activity in PCNSL, frequently leading to durable responses in the relapsed/refractory patients. Many ongoing studies will likely lead to a better understanding of the roles of these treatments, especially as the first line and potentially also as maintenance. In addition, the use of molecular profiling to predict disease response to targeted agents and understand relapse patterns will become increasingly important. Clinical trials in PCNSL are critical yet frequently challenging to conduct given the rarity of the condition and lack of suitable subjects. Therefore, multi-institutional and international collaboration is of utmost importance to accelerate progress in understanding the biology and design better treatments for this disease. It is critical to consider patients of all demographics in the design and study of future treatment algorithms to have the largest impact on patient care and outcomes.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Central Nervous System/pathology ; Central Nervous System Neoplasms/diagnosis ; Central Nervous System Neoplasms/etiology ; Central Nervous System Neoplasms/therapy ; Humans ; Lymphoma/diagnosis ; Lymphoma/etiology ; Lymphoma/therapy ; Lymphoma, Non-Hodgkin/drug therapy ; Methotrexate/therapeutic use ; Neoplasm Recurrence, Local/drug therapy
    Chemical Substances Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2022-02-19
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057351-0
    ISSN 1534-6277 ; 1527-2729
    ISSN (online) 1534-6277
    ISSN 1527-2729
    DOI 10.1007/s11864-021-00921-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The Impact of COVID-19 on Physician-Scientist Trainees and Faculty in the United States: A National Survey.

    Kwan, Jennifer M / Noch, Evan / Qiu, Yuqing / Toubat, Omar / Christophers, Briana / Azzopardi, Stephanie / Gilmer, Gabrielle / Wiedmeier, Julia Erin / Daye, Dania

    Academic medicine : journal of the Association of American Medical Colleges

    2022  Volume 97, Issue 10, Page(s) 1536–1545

    Abstract: Purpose: Physician-scientists have long been considered an endangered species, and their extended training pathway is vulnerable to disruptions. This study investigated the effects of COVID-19-related challenges on the personal lives, career activities, ...

    Abstract Purpose: Physician-scientists have long been considered an endangered species, and their extended training pathway is vulnerable to disruptions. This study investigated the effects of COVID-19-related challenges on the personal lives, career activities, stress levels, and research productivity of physician-scientist trainees and faculty.
    Method: The authors surveyed medical students (MS), graduate students (GS), residents/fellows (R/F), and faculty (F) using a tool distributed to 120 U.S. institutions with MD-PhD programs in April-June 2020. Chi-square and Fisher's exact tests were used to compare differences between groups. Machine learning was employed to select variables for multivariate logistic regression analyses aimed at identifying factors associated with stress and impaired productivity.
    Results: The analyses included 1,929 respondents (MS: n = 679, 35%; GS: n = 676, 35%; R/F: n = 274, 14%; F: n = 300, 16%). All cohorts reported high levels of social isolation, stress from effects of the pandemic, and negative impacts on productivity. R/F and F respondents were more likely than MS and GS respondents to report financial difficulties due to COVID-19. R/F and F respondents with a dual degree expressed more impaired productivity compared with those without a dual degree. Multivariate regression analyses identified impacted research/scholarly activities, financial difficulties, and social isolation as predictors of stress and impaired productivity for both MS and GS cohorts. For both R/F and F cohorts, impacted personal life and research productivity were associated with stress, while dual-degree status, impacted research/scholarly activities, and impacted personal life were predictors of impaired productivity. More female than male respondents reported increased demands at home.
    Conclusions: This national survey of physician-scientist trainees and faculty found a high incidence of stress and impaired productivity related to the COVID-19 pandemic. Understanding the challenges faced and their consequences may improve efforts to support the physician-scientist workforce in the postpandemic period.
    MeSH term(s) Biomedical Research/education ; COVID-19/epidemiology ; Faculty ; Female ; Humans ; Male ; Pandemics ; Physicians ; Students, Medical ; United States/epidemiology
    Language English
    Publishing date 2022-09-23
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 96192-9
    ISSN 1938-808X ; 1040-2446
    ISSN (online) 1938-808X
    ISSN 1040-2446
    DOI 10.1097/ACM.0000000000004802
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women.

    Wiedmeier, Julia Erin / Kato, Catherine / Zhang, Zhenzhen / Lee, Hyunjung / Dunlap, Jennifer / Nutt, Eric / Rattray, Rogan / McKay, Sarah / Eide, Christopher / Press, Richard / Mori, Motomi / Druker, Brian / Dao, Kim-Hien

    Experimental hematology

    2016  Volume 44, Issue 9, Page(s) 857–865.e5

    Abstract: Recent large cohort studies revealed that healthy older individuals harbor somatic mutations that increase their risk for hematologic malignancy and all-cause cardiovascular deaths. The majority of these mutations are in chromatin and epigenetic ... ...

    Abstract Recent large cohort studies revealed that healthy older individuals harbor somatic mutations that increase their risk for hematologic malignancy and all-cause cardiovascular deaths. The majority of these mutations are in chromatin and epigenetic regulatory genes (CERGs). CERGs play a key role in regulation of DNA methylation (DNMT3A and TET2) and histone function (ASXL1) and in clonal proliferation of hematopoietic stem cells. We hypothesize that older women manifesting clonal hematopoiesis, defined here as a functional phenomenon in which a hematopoietic stem cell has acquired a survival and proliferative advantage, harbor a higher frequency of somatic mutations in CERGs. The human androgen receptor gene (HUMARA) assay was used in our study to detect the presence of nonrandom X inactivation in women, a marker for clonal hematopoiesis. In our pilot study, we tested 127 blood samples from women ≥65 years old without a history of invasive cancer or hematologic malignancies. Applying stringent qualitative criteria, we found that 26% displayed clonal hematopoiesis; 52.8% displayed polyclonal hematopoiesis; and 21.3% had indeterminate patterns (too close to call by qualitative assessment). Using Illumina MiSeq next-generation sequencing, we identified somatic mutations in CERGs in 15.2% of subjects displaying clonal hematopoiesis (three ASXL1 and two DNMT3A mutations with an average variant allele frequency of 15.7%, range: 6.3%-23.3%). In a more limited sequencing analysis, we evaluated the frequency of ASXL1 mutations by Sanger sequencing and found mutations in 9.7% of the clonal samples and 0% of the polyclonal samples. By comparing several recent studies (with some caveats as described), we determined the fold enrichment of detecting CERG mutations by using the HUMARA assay as a functional screen for clonal hematopoiesis. We conclude that a functional assay of clonal hematopoiesis is enriching for older women with somatic mutations in CERGs, particularly for ASXL1 and TET2 mutations and less so for DNMT3A mutations.
    MeSH term(s) Age Factors ; Aged ; Aged, 80 and over ; Clonal Evolution/genetics ; DNA (Cytosine-5-)-Methyltransferases/genetics ; Epigenesis, Genetic ; Female ; Gene Expression Regulation, Developmental ; Hematopoiesis/genetics ; Hematopoietic Stem Cells/cytology ; Hematopoietic Stem Cells/metabolism ; High-Throughput Nucleotide Sequencing ; Humans ; Mutation ; Receptors, Androgen/metabolism ; Repressor Proteins/genetics
    Chemical Substances ASXL1 protein, human ; Receptors, Androgen ; Repressor Proteins ; DNA (Cytosine-5-)-Methyltransferases (EC 2.1.1.37) ; DNA methyltransferase 3A (EC 2.1.1.37)
    Language English
    Publishing date 2016-05-26
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 185107-x
    ISSN 1873-2399 ; 0531-5573 ; 0301-472X
    ISSN (online) 1873-2399
    ISSN 0531-5573 ; 0301-472X
    DOI 10.1016/j.exphem.2016.05.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top